The Al Fagih Hospital sale is the one Saudi hospital deal where both sides' first quarter after closing is public. The seller's record profit hid a weaker quarter, and the buyer's rising EBITDA came with a 46% fall in profit.
Fakeeh Care paid SAR 1,595,625,000 for 100% of Dr. Mohammed Al Fagih Hospital in Riyadh, and both sides' Q3 2026 results are now on the Saudi Exchange. Dallah, which sold 31.21%, reported record net profit of SAR 436.1m, of which SAR 356.6m was the disposal gain; underlying profit fell 28.6%. Fakeeh's revenue rose 19.7% and its EBITDA 10%, while net profit fell 45.9% as depreciation and finance cost arrived. The price was for equity, with debt assumed on top. Four of six other listed operators cited receivables in their results.
What a board member needs before the next meeting on this.
- The multiple is higher than it looks. SAR 1,595.6m for the equity is about 14.2 times the hospital's FY2025 EBITDA of SAR 112m on our arithmetic, and Fakeeh also took on the target's net debt. Enterprise value sits above that figure.
- The seller's record quarter was a weaker one. Dallah's Q3 net profit of SAR 436.1m included a SAR 356.6m gain. Underlying profit fell 28.6% to SAR 79.5m and adjusted EBITDA fell 7.0%.
- The buyer's first quarter carries the bill. Fakeeh's EBITDA rose SAR 13m, while depreciation and finance cost rose SAR 36m together on our arithmetic. Net profit fell 45.9%.
- Receivables moved the comparables. Care, SMC, Mouwasat and Saudi German each tied a Q3 result to credit-loss charges, a prior recovery or a receivables restatement. A buyer will ask the same of any seller.
On 5 May 2026 Fakeeh Care signed a binding agreement to buy 100% of Dr. Mohammed Bin Rashed Al Fagih & Partners Company, which runs Dr. Mohammed Al Fagih Hospital in central-east Riyadh, for total cash consideration of SAR 1,595,625,000 (Fakeeh Care SPA announcement). Dallah Healthcare sold 31.21%, Mohammed Rashid Al-Fagih 18.2% and 38 minority holders the remaining 50.59%.
The hospital reported FY2025 revenue of SAR 466m and EBITDA of SAR 112m, and operated 238 beds at 31 December 2025 against capacity for 350. Closing came in July 2026. In the first week of November both sides published their third-quarter results, so this is the one Saudi hospital deal where the seller's gain and the buyer's first quarter as owner sit side by side.
The price was for equity, so the multiple is higher than it looks
On our arithmetic, SAR 1,595.6m is about 14.2 times FY2025 EBITDA and 3.4 times FY2025 revenue, using the figures in the same announcement (Fakeeh Care SPA announcement). That price was paid for the shares. Fakeeh states that its debt will rise through both the acquisition financing and the assumption of the target's existing net debt, an amount it did not disclose, so enterprise value sits above SAR 1,595.6m and the EBITDA multiple above 14.2.
The per-bed figure depends on which beds a seller counts: about SAR 6.7m per operated bed and SAR 4.6m per bed of capacity, on our arithmetic. The announcement says the hospital has headroom to ramp up without material capital expenditure in the medium term. That headroom is part of what the buyer paid for.
The seller's record quarter was a weaker operating quarter
Dallah reported Q3 2026 net profit of SAR 436.1m, against SAR 141.9m a year earlier and its highest quarterly profit on record, including a SAR 356.6m gain on the disposal, net of zakat (Dallah Healthcare Q3 2026 results). Excluding non-recurring items, net profit fell 28.6% to SAR 79.5m and adjusted EBITDA fell 7.0% to SAR 207m.
Expected credit loss expense rose by about SAR 18m. Dallah received the proceeds in July and is applying them to repay financing facilities in phases. On our arithmetic, 31.21% of the consideration is about SAR 498m before any adjustment. For a seller holding a minority stake, the gain is a one-quarter event, and the market reads the underlying number.
Buying, selling or valuing a healthcare business? Talk to the principal who runs the deal. Discuss a transaction
The buyer's EBITDA rose while its profit nearly halved
Fakeeh's Q3 revenue rose 19.7% to SAR 931.3m, and Group revenue excluding the new hospital grew 5% (Fakeeh Care Q3 2026 results). EBITDA rose to SAR 138m from SAR 125m. Net profit fell 45.9% to SAR 38.8m, as depreciation and amortisation rose to SAR 66m from SAR 49m and net finance costs to SAR 28m from SAR 9m on the acquisition financing and the target's own debt.
On our arithmetic, those two lines rose SAR 36m together against an EBITDA gain of SAR 13m. A buyer's board that approves a debt-funded hospital purchase at this multiple should expect the first full quarter to read this way, and a seller should expect the buyer to know it.
Receivables moved four of six other results
Of the six other listed operators that reported in the same window, four tied a Q3 movement to receivables. Care booked expected credit loss provisions of SAR 11.3m against SAR 2.4m in Q2, linked to ongoing commercial negotiations with insurers (Care Q3 2026 results). SMC's general and administrative expenses rose 44.4% year on year, mainly on a higher credit-loss allowance (SMC Q3 2026 results).
Mouwasat's net profit fell 5.8%, against a prior-year quarter that benefited from recovering part of its doubtful receivables (Mouwasat Q3 2026 results). Saudi German restated its comparative quarter, including a SAR 134.2m impairment of reinstated trade receivables, and its reviewer qualified the conclusion on that restatement (Saudi German Q3 2026 results). A buyer pricing a private Saudi hospital will read the seller's receivables against that record.
What a seller prepares before the first meeting
Four numbers decide the conversation. EBITDA on the basis the buyer will use, with one-off items removed in writing. Net debt as the buyer will define it, because it comes off the equity price. Operated, licensed and buildable beds, each with its capital cost, because the buyer will price headroom and resist paying twice for it.
Receivables by payer and ageing bucket, with the allowance against each and three years of write-offs. The Fakeeh agreement also carried a leakage indemnity and customary warranties, and conditions had to be met within six months of signing. Sellers who arrive with those terms drafted negotiate them; sellers who do not, accept them. That preparation is the work of our sell-side M&A practice.
Four questions before you sell a Saudi hospital
- On what EBITDA will the buyer price us, and how much of our debt comes off the headline price?
- Which of our capacity, operated beds or licensed beds, is the buyer paying for?
- What does the gain do to our own reported profit, and what does underlying profit show without it?
- Can we show receivables by payer and the allowance against each before the buyer asks?
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.